With nearly 210 million individuals affected by dry eye syndrome globally, the demand for effective treatment solutions has surged significantly. The condition is particularly prevalent among aging ...

Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...

Pharma segment revenue rose 7% to $326 million. Miebo generated $53 million in Q4 revenue, while Xiidra contributed $104 million. Patrick Wood, Morgan Stanley: Asked about customer engagement ...

If underlying inflammation is present, the prescription eye drop XIIDRA® (lifitegrast ophthalmic solution) 5%, used to treat the signs and symptoms of chronic dry eye by targeting inflammation ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ...

Conversely, Xiidra, another key product in the company's DED portfolio, has been struggling to maintain its market position. This disparity in performance between the two products highlights the ...